Skip to main content

Aspartylglucosaminuria

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Neurogene
NeurogeneNY - New York
1 program
A Natural History Study of AspartylglucosaminuriaN/A1 trial
Active Trials
NCT03853876Terminated8Est. Mar 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NeurogeneA Natural History Study of Aspartylglucosaminuria

Clinical Trials (1)

Total enrollment: 8 patients across 1 trials

NCT03853876NeurogeneA Natural History Study of Aspartylglucosaminuria

A Natural History Study of Aspartylglucosaminuria

Start: Apr 2019Est. completion: Mar 20228 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.